Content Preview
Newsday/Optimum Online® subscribers click here for full access
Not a Newsday or Optimum Online® subscriber? Click here
FDA extends review of XenoPort-Glaxo pain drug
NEW YORK (AP) — The Food and Drug Administration needs three more months to review an application to a neuropathic pain drug being developed by XenoPort Inc. and GlaxoSmithKline PLC, the companies said.
XenoPort and GlaxoSmithKline said late Friday the FDA should complete its review of the drug, called gabapentin enacarbil, by Feb. 9, 2010. The review period was scheduled to end Monday. The...
newsday.com is now available at no charge to Newsday and Optimum Online® subscribers. To continue reading, please log in or register now.
-
Already
registered on
newsday.com?
log in -
Already a subscriber
to Newsday or
Optimum Online®?
get access -
Not a Newsday
or Optimum Online®
subscriber?
click here
